Ultragenyx Pharmaceutical (RARE) Stock Forecast, Price Target & Predictions
RARE Stock Forecast
Ultragenyx Pharmaceutical stock forecast is as follows: an average price target of $108.14 (represents a 84.10% upside from RARE’s last price of $58.74) and a rating consensus of 'Buy', based on 17 wall street analysts offering a 1-year stock forecast.
RARE Price Target
The average price target for Ultragenyx Pharmaceutical (RARE) is $108.14 based on 1-year price targets from 17 Wall Street analysts in the past 3 months, with a price target range of $150.00 to $67.00. This represents a potential 84.10% upside from RARE's last price of $58.74.
RARE Analyst Ratings
According to 17 Wall Street analysts, Ultragenyx Pharmaceutical's rating consensus is 'Buy'. The analyst rating breakdown for RARE stock is 0 'Strong Buy' (0.00%), 14 'Buy' (82.35%), 2 'Hold' (11.76%), 1 'Sell' (5.88%), and 0 'Strong Sell' (0.00%).
Ultragenyx Pharmaceutical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 06, 2024 | Salveen Richter | Goldman Sachs | $67.00 | $41.45 | 61.64% | 14.06% |
| May 31, 2024 | Dae Gon Ha | Stifel Nicolaus | $127.00 | $38.65 | 228.59% | 116.21% |
| May 31, 2024 | Christopher Raymond | Raymond James | $135.00 | $38.65 | 249.29% | 129.83% |
| May 31, 2024 | Joel Beatty | Robert W. Baird | $72.00 | $38.65 | 86.29% | 22.57% |
| May 31, 2024 | Whitney Ijem | Canaccord Genuity | $111.00 | $38.65 | 187.19% | 88.97% |
| Apr 15, 2024 | Dae Gon Ha | Stifel Nicolaus | $124.00 | $42.87 | 189.25% | 111.10% |
| Apr 15, 2024 | Christopher Raymond | Raymond James | $130.00 | $42.87 | 203.24% | 121.31% |
| Feb 03, 2023 | - | Morgan Stanley | $95.00 | $47.03 | 102.00% | 61.73% |
| Dec 30, 2022 | - | H.C. Wainwright | $82.00 | $46.33 | 76.99% | 39.60% |
| Jul 28, 2022 | Christopher Raymond | Piper Sandler | $130.00 | $51.88 | 150.58% | 121.31% |
The latest Ultragenyx Pharmaceutical stock forecast, released on Jun 06, 2024 by Salveen Richter from Goldman Sachs, set a price target of $67.00, which represents a 61.64% increase from the stock price at the time of the forecast ($41.45), and a 14.06% increase from RARE last price ($58.74).
Ultragenyx Pharmaceutical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 7 |
| Avg Price Target | - | - | $109.43 |
| Last Closing Price | $58.74 | $58.74 | $58.74 |
| Upside/Downside | -100.00% | -100.00% | 86.30% |
In the current month, the average price target of Ultragenyx Pharmaceutical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Ultragenyx Pharmaceutical's last price of $58.74. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 02, 2024 | Wedbush | Neutral | Neutral | Hold |
| Aug 02, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| Jul 22, 2024 | Wedbush | Buy | Buy | Hold |
| Jun 17, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 31, 2024 | Barclays | Overweight | Overweight | Hold |
| May 31, 2024 | Wedbush | Buy | Buy | Hold |
| May 31, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
| May 31, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 31, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| May 16, 2024 | Leerink Partners | Outperform | Outperform | Hold |
Ultragenyx Pharmaceutical's last stock rating was published by Wedbush on Aug 02, 2024. The company gave RARE a "Neutral" rating, the same as its previous rate.
Ultragenyx Pharmaceutical Financial Forecast
Ultragenyx Pharmaceutical Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $98.05M | $108.31M | $100.50M | $103.35M | $90.70M | - | $79.94M | $83.39M | $81.65M | $86.97M | $99.39M | $91.54M | $81.47M | $61.71M | $36.31M | $35.59M | $25.80M |
| Avg Forecast | $182.40M | $173.49M | $165.98M | $163.32M | $167.71M | $158.19M | $151.04M | $142.10M | $145.89M | $135.47M | $123.20M | $116.03M | $119.38M | $109.60M | $104.81M | $104.71M | $105.11M | $96.46M | $87.78M | $83.65M | $83.80M | $81.55M | $85.87M | $77.04M | $70.54M | $54.96M | $39.34M | $36.98M | $32.16M | $29.16M |
| High Forecast | $194.00M | $184.52M | $176.53M | $173.70M | $178.37M | $168.25M | $160.65M | $151.14M | $155.17M | $140.70M | $131.03M | $123.41M | $124.59M | $138.19M | $111.47M | $111.37M | $111.80M | $102.59M | $87.78M | $87.74M | $87.89M | $85.54M | $90.06M | $80.81M | $73.99M | $57.65M | $41.27M | $38.79M | $33.73M | $30.58M |
| Low Forecast | $171.55M | $163.17M | $156.11M | $153.61M | $157.73M | $148.78M | $142.06M | $133.65M | $137.22M | $129.12M | $115.87M | $109.13M | $107.11M | $95.70M | $98.57M | $98.49M | $98.86M | $90.72M | $87.78M | $77.45M | $77.58M | $75.50M | $79.50M | $71.32M | $65.31M | $50.88M | $36.42M | $34.24M | $29.77M | $26.99M |
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 4 | 5 | 12 | 9 | 9 | 5 | 5 | 5 | 3 | 4 | 5 | 6 | 3 | 3 | 3 | 3 | 3 | 2 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.89% | 1.03% | 0.96% | 0.98% | 0.94% | - | 0.96% | 1.00% | 1.00% | 1.01% | 1.29% | 1.30% | 1.48% | 1.57% | 0.98% | 1.11% | 0.88% |
Ultragenyx Pharmaceutical's average Quarter revenue forecast for Dec 23 based on 5 analysts is $119.38M, with a low forecast of $107.11M, and a high forecast of $124.59M. RARE's average Quarter revenue forecast represents a 21.75% increase compared to the company's last Quarter revenue of $98.05M (Sep 23).
Ultragenyx Pharmaceutical EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 4 | 5 | 12 | 9 | 9 | 5 | 5 | 5 | 3 | 4 | 5 | 6 | 3 | 3 | 3 | 3 | 3 | 2 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-145.10M | $-147.96M | $-147.51M | $-139.25M | $-222.69M | - | $-131.76M | $-115.10M | $-60.92M | $-110.33M | $-123.98M | $-12.61M | $-56.86M | $37.34M | $-107.68M | $-87.94M | $-110.56M |
| Avg Forecast | $-182.40M | $-173.49M | $-165.98M | $-163.32M | $-167.71M | $-158.19M | $-151.04M | $-142.10M | $-145.89M | $-135.47M | $-123.20M | $-170.61M | $-119.38M | $-109.60M | $-104.81M | $-134.87M | $-105.11M | $-83.41M | $-87.78M | $-106.62M | $-74.12M | $-75.83M | $-95.67M | $-109.92M | $-31.09M | $-62.72M | $-39.34M | $-83.97M | $-89.54M | $-92.13M |
| High Forecast | $-171.55M | $-163.17M | $-156.11M | $-153.61M | $-157.73M | $-148.78M | $-142.06M | $-133.65M | $-137.22M | $-129.12M | $-115.87M | $-136.49M | $-107.11M | $-95.70M | $-98.57M | $-107.90M | $-98.86M | $-66.73M | $-87.78M | $-85.30M | $-59.29M | $-60.66M | $-76.54M | $-87.94M | $-24.87M | $-50.18M | $-36.42M | $-67.17M | $-71.63M | $-73.70M |
| Low Forecast | $-194.00M | $-184.52M | $-176.53M | $-173.70M | $-178.37M | $-168.25M | $-160.65M | $-151.14M | $-155.17M | $-140.70M | $-131.03M | $-204.74M | $-124.59M | $-138.19M | $-111.47M | $-161.85M | $-111.80M | $-100.09M | $-87.78M | $-127.94M | $-88.94M | $-90.99M | $-114.81M | $-131.91M | $-37.30M | $-75.27M | $-41.27M | $-100.76M | $-107.45M | $-110.56M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.32% | 1.41% | 1.09% | 1.32% | 2.67% | - | 1.24% | 1.55% | 0.80% | 1.15% | 1.13% | 0.41% | 0.91% | -0.95% | 1.28% | 0.98% | 1.20% |
3 analysts predict RARE's average Quarter EBITDA for Sep 20 to be $-62.72M, with a high of $-50.18M and a low of $-75.27M. This is -267.97% lower than Ultragenyx Pharmaceutical's previous annual EBITDA (Jun 20) of $37.34M.
Ultragenyx Pharmaceutical Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 4 | 5 | 12 | 9 | 9 | 5 | 5 | 5 | 3 | 4 | 5 | 6 | 3 | 3 | 3 | 3 | 3 | 2 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-159.65M | $-159.83M | $-163.97M | $-151.83M | $-245.11M | - | $-152.32M | $-122.46M | $-73.00M | $-122.43M | $-136.14M | $-24.01M | $-68.84M | $25.32M | $-119.03M | $-93.81M | $-112.99M |
| Avg Forecast | - | $-12.12M | $-15.58M | $-25.11M | $-102.17M | $-109.20M | $-115.63M | $-123.23M | $-119.48M | $-126.87M | $-143.78M | $-184.19M | $-147.83M | $-179.85M | $-180.99M | $-145.61M | $-184.85M | $-99.95M | $-147.54M | $-115.11M | $-78.86M | $-90.86M | $-106.17M | $-120.71M | $-59.19M | $-75.95M | $51.63M | $-92.81M | $-95.51M | $-94.16M |
| High Forecast | - | $-11.18M | $-14.38M | $-23.17M | $-94.27M | $-100.76M | $-106.69M | $-113.71M | $-110.24M | $-101.85M | $-132.67M | $-147.36M | $-116.47M | $-135.33M | $-167.00M | $-116.49M | $-170.56M | $-79.96M | $-147.54M | $-92.08M | $-63.08M | $-72.69M | $-84.93M | $-96.57M | $-47.35M | $-60.76M | $61.96M | $-74.25M | $-76.41M | $-75.33M |
| Low Forecast | - | $-13.12M | $-16.87M | $-27.18M | $-110.61M | $-118.23M | $-125.19M | $-133.42M | $-129.36M | $-144.73M | $-155.67M | $-221.03M | $-219.50M | $-236.60M | $-195.95M | $-174.73M | $-200.13M | $-119.94M | $-147.54M | $-138.13M | $-94.63M | $-109.04M | $-127.40M | $-144.85M | $-71.03M | $-91.14M | $41.31M | $-111.37M | $-114.61M | $-112.99M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.89% | 0.88% | 1.13% | 0.82% | 2.45% | - | 1.32% | 1.55% | 0.80% | 1.15% | 1.13% | 0.41% | 0.91% | 0.49% | 1.28% | 0.98% | 1.20% |
Ultragenyx Pharmaceutical's average Quarter net income forecast for Sep 20 is $-75.95M, with a range of $-91.14M to $-60.76M. RARE's average Quarter net income forecast represents a -400.01% decrease compared to the company's last Quarter net income of $25.32M (Jun 20).
Ultragenyx Pharmaceutical SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 4 | 5 | 12 | 9 | 9 | 5 | 5 | 5 | 3 | 4 | 5 | 6 | 3 | 3 | 3 | 3 | 3 | 2 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $74.92M | $81.40M | $76.65M | $72.85M | $69.84M | - | $67.31M | $59.43M | $53.88M | $53.41M | $53.26M | $51.04M | $42.12M | $42.25M | $47.52M | $41.88M | $41.01M |
| Avg Forecast | $158.22M | $150.49M | $143.98M | $141.67M | $145.48M | $137.22M | $131.03M | $123.27M | $126.55M | $117.51M | $106.87M | $81.40M | $103.56M | $95.07M | $90.91M | $64.35M | $91.18M | $73.78M | $76.15M | $50.87M | $38.27M | $67.07M | $46.32M | $47.22M | $61.19M | $46.47M | $34.13M | $32.08M | $27.90M | $25.29M |
| High Forecast | $168.29M | $160.06M | $153.14M | $150.68M | $154.73M | $145.95M | $139.36M | $131.10M | $134.60M | $122.05M | $113.66M | $97.68M | $108.08M | $119.87M | $96.70M | $77.22M | $96.98M | $88.53M | $76.15M | $61.04M | $45.92M | $80.49M | $55.58M | $56.67M | $64.19M | $55.76M | $35.80M | $33.65M | $29.26M | $26.53M |
| Low Forecast | $148.82M | $141.55M | $135.42M | $133.25M | $136.83M | $129.06M | $123.23M | $115.94M | $119.03M | $112.01M | $100.51M | $65.12M | $92.91M | $83.02M | $85.51M | $51.48M | $85.76M | $59.02M | $76.15M | $40.69M | $30.62M | $53.66M | $37.05M | $37.78M | $56.65M | $37.18M | $31.60M | $29.70M | $25.83M | $23.42M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.79% | 0.90% | 1.19% | 0.80% | 0.95% | - | 1.32% | 1.55% | 0.80% | 1.15% | 1.13% | 0.83% | 0.91% | 1.24% | 1.48% | 1.50% | 1.62% |
Ultragenyx Pharmaceutical's average Quarter SG&A projection for Dec 23 is $103.56M, based on 5 Wall Street analysts, with a range of $92.91M to $108.08M. The forecast indicates a 38.23% rise compared to RARE last annual SG&A of $74.92M (Sep 23).
Ultragenyx Pharmaceutical EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 5 | 6 | 12 | 6 | 4 | 5 | 12 | 9 | 9 | 5 | 5 | 5 | 3 | 4 | 5 | 6 | 3 | 3 | 3 | 3 | 3 | 2 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-2.23 | $-0.00 | $-2.33 | $-2.16 | $-3.50 | - | $-2.19 | $-1.79 | $-1.08 | $-1.81 | $-2.03 | $-0.37 | $-1.13 | $0.42 | $-2.05 | $-1.62 | $-1.96 |
| Avg Forecast | - | $-0.14 | $-0.18 | $-0.29 | $-1.18 | $-1.26 | $-1.34 | $-1.42 | $-1.38 | $-1.47 | $-1.66 | $-1.75 | $-1.71 | $-2.08 | $-2.09 | $-1.99 | $-2.13 | $-1.81 | $-1.75 | $-1.78 | $-1.37 | $-1.39 | $-1.32 | $-1.24 | $-1.16 | $-1.28 | $-1.59 | $-1.62 | $-1.59 | $-1.65 |
| High Forecast | - | $-0.13 | $-0.17 | $-0.27 | $-1.09 | $-1.16 | $-1.23 | $-1.31 | $-1.27 | $-1.18 | $-1.53 | $-1.61 | $-1.35 | $-1.56 | $-1.93 | $-1.84 | $-1.97 | $-1.67 | $-1.75 | $-1.61 | $-1.24 | $-1.26 | $-1.19 | $-1.12 | $-1.05 | $-1.16 | $-1.44 | $-1.46 | $-1.44 | $-1.49 |
| Low Forecast | - | $-0.15 | $-0.19 | $-0.31 | $-1.28 | $-1.37 | $-1.45 | $-1.54 | $-1.49 | $-1.67 | $-1.80 | $-1.89 | $-2.54 | $-2.73 | $-2.26 | $-2.16 | $-2.31 | $-1.96 | $-1.75 | $-1.89 | $-1.46 | $-1.48 | $-1.41 | $-1.32 | $-1.24 | $-1.36 | $-1.69 | $-1.72 | $-1.69 | $-1.76 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.07% | 0.00% | 1.17% | 1.01% | 1.93% | - | 1.23% | 1.30% | 0.78% | 1.37% | 1.63% | 0.32% | 0.88% | -0.26% | 1.27% | 1.02% | 1.18% |
According to 3 Wall Street analysts, Ultragenyx Pharmaceutical's projected average Quarter EPS for Sep 20 is $-1.28, with a low estimate of $-1.36 and a high estimate of $-1.16. This represents a -405.55% decrease compared to RARE previous annual EPS of $0.42 (Jun 20).
Ultragenyx Pharmaceutical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| ARVN | Arvinas | $25.05 | $75.36 | 200.84% | Buy |
| PDSB | PDS Bio | $3.00 | $9.00 | 200.00% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
| RARE | Ultragenyx Pharmaceutical | $58.74 | $108.14 | 84.10% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| KURA | Kura Oncology | $20.88 | $28.67 | 37.31% | Buy |
| CRNX | Crinetics Pharmaceuticals | $53.80 | $70.14 | 30.37% | Buy |
| INCY | Incyte | $63.56 | $81.00 | 27.44% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| ALNY | Alnylam Pharmaceuticals | $265.27 | $250.16 | -5.70% | Buy |
| UTHR | United Therapeutics | $339.12 | $312.50 | -7.85% | Buy |
RARE Forecast FAQ
Is Ultragenyx Pharmaceutical a good buy?
Yes, according to 17 Wall Street analysts, Ultragenyx Pharmaceutical (RARE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 14 'Buy' recommendations, accounting for 82.35% of RARE's total ratings.
What is RARE's price target?
Ultragenyx Pharmaceutical (RARE) average price target is $108.14 with a range of $67 to $150, implying a 84.10% from its last price of $58.74. The data is based on 17 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Ultragenyx Pharmaceutical stock go up soon?
According to Wall Street analysts' prediction for RARE stock, the company can go up by 84.10% (from the last price of $58.74 to the average price target of $108.14), up by 155.36% based on the highest stock price target, and up by 14.06% based on the lowest stock price target.
Can Ultragenyx Pharmaceutical stock reach $90?
RARE's average twelve months analyst stock price target of $108.14 supports the claim that Ultragenyx Pharmaceutical can reach $90 in the near future.
What are Ultragenyx Pharmaceutical's analysts' financial forecasts?
Ultragenyx Pharmaceutical's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $619.04M (high $658.4M, low $582.23M), average EBITDA is $-619M (high $-582M, low $-658M), average net income is $-450M (high $-415M, low $-487M), average SG&A $536.99M (high $571.14M, low $505.06M), and average EPS is $-5.2 (high $-4.798, low $-5.63). RARE's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $685.19M (high $728.75M, low $644.44M), average EBITDA is $-685M (high $-644M, low $-729M), average net income is $-52.814M (high $-48.732M, low $-57.18M), average SG&A $594.37M (high $632.16M, low $559.03M), and average EPS is $-0.61 (high $-0.563, low $-0.66).
Did the RARE's actual financial results beat the analysts' financial forecasts?
Based on Ultragenyx Pharmaceutical's last annual report (Dec 2022), the company's revenue was $363.33M, which missed the average analysts forecast of $373.01M by -2.60%. Apple's EBITDA was $-639M, beating the average prediction of $-383M by 66.98%. The company's net income was $-707M, beating the average estimation of $-547M by 29.22%. Apple's SG&A was $278.14M, missing the average forecast of $291.98M by -4.74%. Lastly, the company's EPS was $-10.12, beating the average prediction of $-7.478 by 35.34%. In terms of the last quarterly report (Sep 2023), Ultragenyx Pharmaceutical's revenue was $98.05M, missing the average analysts' forecast of $109.6M by -10.53%. The company's EBITDA was $-145M, beating the average prediction of $-110M by 32.39%. Ultragenyx Pharmaceutical's net income was $-160M, missing the average estimation of $-180M by -11.23%. The company's SG&A was $74.92M, missing the average forecast of $95.07M by -21.20%. Lastly, the company's EPS was $-2.23, beating the average prediction of $-2.077 by 7.35%